Clinical Trial Update: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]

View source ↗

Summary

A 3-month Phase 3 safety study of ONS-5010 in subjects with visual impairment due to retinal disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Branch Retinal Vein Occlusion
• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• ONS-5010

Snippet

Sponsor: Outlook Therapeutics, Inc. | Conditions: Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED